Wiśniowa (PL) Cancer Clinical Trials

Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)

~26 mi. (Rzeszów, Poland, +30 more cities)

Mrukmed-Mrukmed ( Site 0901)

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Colorectal Adenocarcinoma

MK-1308A, +4 more drugs

immunotherapy

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

~27 mi. (Brzozów, Poland, +202 more cities)

Site PL48002

CLDN18 Expression, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

modified FOLFOX6 regimen, +1 more drug

chemotherapy, +1 more type

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

~27 mi. (Brzozów, Poland, +72 more cities)

Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza

del(11)(q10), +27 more biomarkers

Primary Myelofibrosis, +1 more condition

navtemadlin

targeted therapy

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~42 mi. (Tarnów, Poland, +163 more cities)

Szpital Wojewodzki ( Site 1062)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~67 mi. (Przemyśl, Poland, +93 more cities)

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1053)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~67 mi. (Przemyśl, Poland, +131 more cities)

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1702)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

~67 mi. (Przemyśl, Poland, +228 more cities)

Wojewodzki Szpital im. Sw. Ojca Pio /ID# 231960

MET Expression

Non-Small Cell Lung Carcinoma

telisotuzumab vedotin

chemotherapy, +1 more type

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

~67 mi. (Przemyśl, Poland, +34 more cities)

Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu ( Site 0249)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

immunotherapy, +1 more type